OTIMA

Ottimo Pharma is a clinical-stage biotechnology company focused on developing next-generation bi-functional medicines for the treatment of cancer. The company's lead program, OTP-01, is a first-in-class, dual-paratopic, single-agent antibody that simultaneously targets PD-1 and VEGFR2. By combining immune checkpoint inhibition with anti-angiogenic activity in a single molecule, Ottimo aims to overcome the limitations of current combination therapies and improve outcomes for patients with solid tumors. The company is led by a team of experienced oncology drug developers and recently initiated a Phase I/IIA adaptive clinical study to evaluate the safety and efficacy of OTP-01.